News

Kuros Biosciences Inaugurates New US Site

Schlieren, ZH/Alpharetta — Kuros Biosciences AG, based in Schlieren, marks the first step toward commissioning a new plant in the US with a symbolic ribbon-cutting ceremony. The official opening will follow in July 2026. According to a press release, Kuros Biosciences took the "first step" in its US expansion by cutting...

read more

LS2 Annual Meeting 2026 in Zurich

We are excited to invite you to the LS2 Annual Meeting 2026, Switzerland’s premier life sciences event, held at the Irchel Campus of the University of Zürich from February 11 to 12, 2026! The meeting will kick off with the Young Scientists’ Satellite on February 10. We hope to bring...

read more

Virometix Announces Completion of Enrollment in Phase I Trial of V-212 — a Fully Synthetic, Serotype-Independent Vaccine Candidate Against Streptococcus Pneumoniae

SCHLIEREN, Switzerland--(BUSINESS WIRE)--Virometix AG, a Swiss clinical-stage biotechnology company pioneering fully synthetic vaccines, today announced that it has successfully completed enrollment in the Phase I clinical trial of V-212, a peptide-based, serotype-independent vaccine candidate targeting Streptococcus pneumoniae infections. “Completing enrollment in this Phase I trial marks a significant milestone for V-212,”...

read more

DINAMIQS opens cGMP manufacturing facility for viral vectors

DINAMIQS, a Siegfried company (SIX: SFZN), today inaugurated its state-of-the-art cGMP manufacturing facility for viral vectors — the first of its kind in Switzerland. The new facility enables end-to-end manufacturing of viral vector gene therapies, from molecule design to aseptic drug product filling. As part of this facility, new lab...

read more